Stocktoria
Dogwood Therapeutics, Inc. DWTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-12-17
Dogwood Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $21.9M | $3.5M | $1.7M | $8.1M | $10.8M |
| Operating income | -$28.0M | -$12.2M | -$5.4M | -$12.3M | -$15.6M |
| Income tax | $221,096 | -$503 | — | — | — |
| Net income | -$34.3M | -$12.3M | -$5.3M | -$12.2M | -$16.0M |
| EPS (diluted) | $-7.13 | $-12.52 | $-7.05 | $-1.11 | $-1.92 |
| Operating cash flow | -$15.6M | -$8.8M | -$4.9M | -$11.5M | -$15.7M |
| Cash & equivalents | $6.5M | $14.8M | $3.3M | $7.0M | $14.0M |
| Total assets | $90.2M | $94.3M | $4.2M | $8.4M | $15.8M |
| Total liabilities | $15.3M | $30.0M | $358,548 | $1.0M | $1.3M |
| Shareholders' equity | $74.9M | -$10.1M | $3.8M | $7.3M | $14.5M |
Source: SEC EDGAR filings · CIK 0001818844 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.